Prana Biotechnology (ATHE)
(Delayed Data from NSDQ)
$1.38 USD
+0.02 (1.47%)
Updated Aug 15, 2024 03:19 PM ET
After-Market: $1.37 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.38 USD
+0.02 (1.47%)
Updated Aug 15, 2024 03:19 PM ET
After-Market: $1.37 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Zacks News
Alterity (ATHE) Up on Interim Data From Advance MSA Study
by Zacks Equity Research
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
by Zacks Equity Research
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.